Evaxion Biotech A/S (EVAX), a leading TechBio company in the clinical phase, known for its expertise in AI-driven vaccine development, has successfully completed dosing for all 16 participants in its Phase 2 trial of EVX-01, the company's primary asset. EVX-01 is a personalized cancer vaccine developed using Evaxion's AI-Immunology platform and is intended to treat advanced melanoma, a type of skin cancer.
The dosing has concluded in accordance with the trial's established protocol and timeline, ensuring the trial remains on schedule for its anticipated data release in the latter half of 2025. Significantly, the first patient has fully completed their participation and attended their final visit as outlined in the trial protocol. Monitoring and data collection efforts continue for the other participants.
As the trial moves forward, Evaxion Biotech is optimistic that EVX-01 could represent a significant advancement in the treatment of melanoma, which ranks among the most prevalent and aggressive skin cancers.
Currently, EVAX shares are trading at $3.48, reflecting a decline of 6.45% or $0.24 on the Nasdaq.
